Akcea Therapeutics Names Tracy Palmer Berns Chief Compliance Officer

Tracy Palmer Berns has joined rare disease drug developer Akcea Therapeutics (NASDAQ: [[ticker:AKCA]]) as chief compliance officer, the same role she held most recently at AMAG Pharmaceuticals (NASDAQ: [[ticker:AMAG]]). Her experience also includes compliance and regulatory positions at Medtronic (NYSE: [[ticker:MDT]]) and Covidien, which Medtronic acquired in 2015. Boston-based Akcea has two commercialized products: hereditary transthyretin amyloidosis treatment inotersen (Tegsedi) and volanesorsen (Waylivra) for familial chylomicronemia syndrome.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.